CIRM awarded $7.4M to a UC San Diego team to complete preclinical safety, off‑target testing and manufacturing scale‑up for a CRISPR‑edited stem‑cell therapy for Friedreich’s ataxia.

Qualcomm integrates Snapdragon technology in Toyota RAV4, enhancing the SUV's connectivity and safety features.

Birch Aquarium staff are caring for more than 3,000 red octopus hatchlings behind the scenes, a rare husbandry milestone for the La Jolla facility.

A Deep Origin‑led consortium won up to $31.7M from ARPA‑H; La Jolla’s Sanford Burnham Prebys will help build AI and tissue models to predict toxicity and speed drug development.

UC San Diego is expanding access to chip design with OpenROAD, a new NSF-backed Chipshub and DARPA funding that together aim to speed student work to real silicon.

A UC San Diego‑led team won Curebound’s $1M Cure Prize to build a multi‑modal AI that could find pancreatic cancer earlier. The award is meant to push promising algorithms toward clinical use.

San Diego County Supervisors voted to explore new options for the storage and removal of nuclear waste from the San Onofre Nuclear Generating Station.

Alexander Khalessi will lead UC San Diego Health’s AI and technology strategy while remaining a clinical leader. The appointment aims to scale pilots into systemwide tools.

San Diego's Kura Oncology and partner Kyowa Kirin won FDA approval for Komzifti, an oral therapy for relapsed NPM1‑mutated AML. The companies are preparing a U.S. launch and expanded trials.

Researchers found an F1 hybrid eelgrass in Mission Bay with genes tied to low‑light tolerance — a potential pathway to more successful, genome‑aware restorations.

SDSC simulations link Parkinson’s beta waves to dysfunction in PT5B motor‑cortex neurons, suggesting a precise, cell‑level treatment target. The work was run on UC San Diego’s Expanse system.

Universities across San Diego are adding AI degrees, clinics and labs to meet growing employer demand while students and workers wrestle with uncertainty.

San Diego startups raised just $590M in Q3 — the smallest quarterly total in eight years — as investors concentrate capital into a few giant AI and biotech deals. Local founders now face a tighter fundraising market and brighter prospects for M&A.